56 results
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
provides intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may … supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may also allow … basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
provides intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used … with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase
8-K
EX-99.1
jyg01zu2t0gmxnmb1
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
sk8fxgl0 e8p
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
lbgkhujzgr0b lj6
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
ln9dan
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
pi5l8jrkma9e4lds5uz
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
kvly1ezeak4 rk9
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
ym0 xii3bts5ned226z
15 Apr 21
Other Events
12:00am
8-K
EX-99.2
ogonjtk
15 Apr 21
Other Events
12:00am
8-K
EX-1.1
qxezl4z
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
424B5
pe2b nm5cbwpeb6qr
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
wg88 b3j2
22 Oct 19
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
3kkpkjawpt98qigf9
29 Apr 19
Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
4:03pm
424B3
pwbowku2i6j03f30d4fc
12 Apr 19
Prospectus supplement
4:41pm